CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00162331|
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : April 15, 2011
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction||Drug: Technetium Tc99m Sestamibi||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||74 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||AIR-MI: Assessment of Ischemia and Remodeling Following Acute Myocardial Infarction|
|Study Start Date :||January 2005|
|Primary Completion Date :||July 2007|
|Study Completion Date :||July 2007|
- To better understand the interactions between the abnormalities in blood supply from the small vessels of the heart to the heart muscle after a heart attack and the changes in heart size 6 months after the heart attack.
- To estimate the frequency of residual ischemia as assessed by stress myocardial perfusion imaging (MPI) in patients undergoing primary PCI for AMI.
- To estimate the 6-month cardiac event rates (composite of death, another heart attack, hospitalization for heart failure, and irregular heart beats requiring treatment).
- To determine the relationship between changes (from baseline) in LV systolic volume index and LVEF, as measured by gated SPECT imaging 6 months following reperfusion, and the presence and severity of residual ischemia.
- To measure the performance of angiographic parameters of success of reperfusion therapy (TIMI frame count and TIMI myocardial perfusion grade) in predicting the presence of residual ischemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00162331
|United States, Alabama|
|Birmingham, Alabama, United States|
|United States, Massachusetts|
|Boston, Massachusetts, United States|
|United States, Tennessee|
|Nashville, Tennessee, United States|
|United States, Washington|
|Seattle, Washington, United States|
|Sao Paolo, Brazil|
|Ottawa, Ontario, Canada|
|Toronto, Ontario, Canada|
|Study Director:||Qi Zhu, MD||Lantheus Medical Imaging|